Other Non-current Assets - Narrative (Details) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2024 USD ($) payment royalty_payment	Jun. 30, 2023 USD ($)	Sep. 30, 2020 USD ($)	Jun. 30, 2020 USD ($)	Jun. 30, 2024 USD ($) payment	Jun. 30, 2023 USD ($)	Dec. 31, 2023 payment
Acquired Finite-Lived Intangible Assets [Line Items]
Revenues	$ 20,099	$ 13,241			$ 32,152	$ 24,375
Number of guaranteed royalty payments | royalty_payment	8
License agreement with Sunovion Pharmaceuticals, Inc.
Acquired Finite-Lived Intangible Assets [Line Items]
Minimum annual royalty receivable	$ 1,000			$ 1,000	$ 1,000
Number of annual royalty payments receivable | payment	4				4		5
Mitsubishi Tanabe Pharma America, Inc And Haisco For Exarvan
Acquired Finite-Lived Intangible Assets [Line Items]
Sales commissions and fees	$ 191
Royalty
Acquired Finite-Lived Intangible Assets [Line Items]
Revenues					$ (922)	$ (989)
Royalty | License agreement with Sunovion Pharmaceuticals, Inc.
Acquired Finite-Lived Intangible Assets [Line Items]
Revenues			$ 8,000	$ 8,000